AstraZeneca (LON:AZN) PT Set at GBX 9,500 by JPMorgan Chase & Co.
AstraZeneca (LON:AZN) has been given a GBX 9,500 ($124.13) target price by stock analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 12.33% from the company’s current price.
AZN has been the subject of several other reports. Barclays set a GBX 9,300 ($121.52) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Jefferies Financial Group set a GBX 8,000 ($104.53) price target on shares of AstraZeneca and gave the stock a “neutral” rating in a research note on Wednesday, September 9th. Berenberg Bank reissued a “buy” rating and issued a £105 ($137.20) price objective on shares of AstraZeneca in a report on Tuesday. UBS Group set a GBX 7,300 ($95.39) price objective on AstraZeneca and gave the company a “sell” rating in a report on Wednesday, September 9th. Finally, DZ Bank increased their price objective on AstraZeneca from GBX 7,300 ($95.39) to GBX 7,500 ($98.00) and gave the company a “sell” rating in a report on Friday, July 31st. Six equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 8,420 ($110.02).
Shares of AZN opened at GBX 8,457 ($110.51) on Tuesday. The stock has a market capitalization of $110.98 billion and a P/E ratio of 52.16. AstraZeneca has a twelve month low of GBX 5,871 ($76.72) and a twelve month high of £101.20 ($132.24). The company has a 50 day moving average of GBX 8,464.14 and a 200-day moving average of GBX 8,237.73. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 161.97.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: 52-Week High/Low
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.